The University of Chicago Header Logo

Connection

Hedy Kindler to Mesothelioma

Back to Details
This is a "connection" page, showing publications Hedy Kindler has written about Mesothelioma.
Hedy Kindler
Connection Strength
17.965
Mesothelioma
  1. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Nov; 19(11):1564-1577.
    View in: PubMed
    Score: 0.757
  2. Systemic Therapy for Mesothelioma: Turning the Corner. JCO Oncol Pract. 2022 06; 18(6):e843-e845.
    View in: PubMed
    Score: 0.629
  3. Understanding the new therapeutic options for mesothelioma. Lancet Oncol. 2021 10; 22(10):1353-1355.
    View in: PubMed
    Score: 0.616
  4. Reply to D. de Fonseka et al. J Clin Oncol. 2018 09 10; 36(26):2746-2747.
    View in: PubMed
    Score: 0.493
  5. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018 04; 14(4):256-264.
    View in: PubMed
    Score: 0.484
  6. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 05 01; 36(13):1343-1373.
    View in: PubMed
    Score: 0.479
  7. The Challenge of Defining Treatment Standards for a Rare Disease: Malignant Peritoneal Mesothelioma. J Oncol Pract. 2016 10; 12(10):936-937.
    View in: PubMed
    Score: 0.438
  8. MARS: a sense of perspective and an inconvenient truth. J Thorac Oncol. 2013 May; 8(5):e49-50.
    View in: PubMed
    Score: 0.346
  9. Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book. 2013; 182-8.
    View in: PubMed
    Score: 0.338
  10. Robust data: the essential foundation of a revised staging system for pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1623-4.
    View in: PubMed
    Score: 0.334
  11. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.
    View in: PubMed
    Score: 0.328
  12. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012 Sep; 77(3):567-71.
    View in: PubMed
    Score: 0.326
  13. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15.
    View in: PubMed
    Score: 0.325
  14. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012 Jun; 76(3):393-6.
    View in: PubMed
    Score: 0.315
  15. Surgery for mesothelioma? The debate continues. Lancet Oncol. 2011 Aug; 12(8):713-4.
    View in: PubMed
    Score: 0.304
  16. Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011 Feb; 32(1):102-10.
    View in: PubMed
    Score: 0.300
  17. Computerized segmentation and measurement of malignant pleural mesothelioma. Med Phys. 2011 Jan; 38(1):238-44.
    View in: PubMed
    Score: 0.294
  18. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009 Sep; 136(3):888-896.
    View in: PubMed
    Score: 0.268
  19. Malignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90.
    View in: PubMed
    Score: 0.259
  20. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol. 2008 Jun; 9(2-3):171-9.
    View in: PubMed
    Score: 0.250
  21. Current state and future directions of pleural mesothelioma imaging. Lung Cancer. 2008 Mar; 59(3):411-20.
    View in: PubMed
    Score: 0.238
  22. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer. 2006 May; 52(2):141-8.
    View in: PubMed
    Score: 0.211
  23. Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am. 2005 Dec; 19(6):1137-45, viii.
    View in: PubMed
    Score: 0.207
  24. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005 Jun; 48(3):423-8.
    View in: PubMed
    Score: 0.196
  25. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. Lung Cancer. 2024 Sep; 195:107928.
    View in: PubMed
    Score: 0.189
  26. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer. 2004 Aug; 45 Suppl 1:S125-7.
    View in: PubMed
    Score: 0.188
  27. The emerging role of pemetrexed for the treatment of malignant mesothelioma. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):49-53.
    View in: PubMed
    Score: 0.187
  28. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1339-1351.
    View in: PubMed
    Score: 0.185
  29. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for the "N" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1326-1338.
    View in: PubMed
    Score: 0.185
  30. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Apr 01; 10(4):475-483.
    View in: PubMed
    Score: 0.184
  31. The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the "T" Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2024 Sep; 19(9):1310-1325.
    View in: PubMed
    Score: 0.184
  32. ASO Author Reflections: Venous Thromboembolism in Peritoneal Mesothelioma. Ann Surg Oncol. 2024 Jun; 31(6):3785-3786.
    View in: PubMed
    Score: 0.184
  33. Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk. Ann Surg Oncol. 2024 May; 31(5):3339-3349.
    View in: PubMed
    Score: 0.183
  34. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma. J Thorac Oncol. 2024 Aug; 19(8):1242-1252.
    View in: PubMed
    Score: 0.182
  35. Mesothelioma in situ of the peritoneum: report of three cases and review of the literature. Histopathology. 2024 Feb; 84(3):492-506.
    View in: PubMed
    Score: 0.180
  36. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology. Am J Clin Pathol. 2023 09 01; 160(3):238-246.
    View in: PubMed
    Score: 0.177
  37. The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Updated Modeling of Prognostic Factors in Pleural Mesothelioma. J Thorac Oncol. 2023 12; 18(12):1689-1702.
    View in: PubMed
    Score: 0.176
  38. Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma. JAMA Netw Open. 2023 08 01; 6(8):e2327351.
    View in: PubMed
    Score: 0.176
  39. Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation. Cancer. 2023 07 15; 129(14):2152-2160.
    View in: PubMed
    Score: 0.172
  40. A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20.
    View in: PubMed
    Score: 0.167
  41. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 07; 17(7):873-889.
    View in: PubMed
    Score: 0.161
  42. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdom Radiol (NY). 2022 05; 47(5):1725-1740.
    View in: PubMed
    Score: 0.160
  43. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol. 2002 Feb; 29(1):70-6.
    View in: PubMed
    Score: 0.159
  44. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021 06; 9(6):613-621.
    View in: PubMed
    Score: 0.150
  45. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001 Feb-Mar; 31(2-3):311-7.
    View in: PubMed
    Score: 0.148
  46. Malignant pleural mesothelioma. Curr Treat Options Oncol. 2000 Oct; 1(4):313-26.
    View in: PubMed
    Score: 0.144
  47. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999 Nov 15; 86(10):1985-91.
    View in: PubMed
    Score: 0.136
  48. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020 01; 15(1):29-49.
    View in: PubMed
    Score: 0.135
  49. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
    View in: PubMed
    Score: 0.134
  50. Reply to K. Masuda et al. J Clin Oncol. 2019 09 01; 37(25):2294-2295.
    View in: PubMed
    Score: 0.133
  51. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2019 10 01; 25(19):5787-5798.
    View in: PubMed
    Score: 0.132
  52. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019 04 30; 116(18):9008-9013.
    View in: PubMed
    Score: 0.130
  53. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019 04 01; 37(10):790-798.
    View in: PubMed
    Score: 0.129
  54. Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma. Eur Radiol. 2019 Jun; 29(6):2981-2988.
    View in: PubMed
    Score: 0.128
  55. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.
    View in: PubMed
    Score: 0.126
  56. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.
    View in: PubMed
    Score: 0.126
  57. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol. 2018 10 01; 36(28):2863-2871.
    View in: PubMed
    Score: 0.125
  58. Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol. 2019 Feb; 29(2):682-688.
    View in: PubMed
    Score: 0.124
  59. Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. World J Surg. 2018 04; 42(4):1036-1045.
    View in: PubMed
    Score: 0.121
  60. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther. 2018 04 03; 19(4):316-327.
    View in: PubMed
    Score: 0.121
  61. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273.
    View in: PubMed
    Score: 0.116
  62. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist. 2017 02; 22(2):189-198.
    View in: PubMed
    Score: 0.112
  63. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma. Ann Thorac Surg. 2017 Mar; 103(3):962-966.
    View in: PubMed
    Score: 0.110
  64. The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2112-2119.
    View in: PubMed
    Score: 0.109
  65. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2089-2099.
    View in: PubMed
    Score: 0.109
  66. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016 12; 11(12):2100-2111.
    View in: PubMed
    Score: 0.109
  67. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. Sci Rep. 2016 09 13; 6:32992.
    View in: PubMed
    Score: 0.109
  68. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016 Oct; 102(4):1059-66.
    View in: PubMed
    Score: 0.109
  69. Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. Sci Rep. 2016 Apr 15; 6:24578.
    View in: PubMed
    Score: 0.106
  70. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016 Jun; 49(6):1642-7.
    View in: PubMed
    Score: 0.104
  71. Extended Pleurectomy and Decortication for Malignant Pleural Mesothelioma Is an Effective and Safe Cytoreductive Surgery in the Elderly. Ann Thorac Surg. 2015 Nov; 100(5):1868-74.
    View in: PubMed
    Score: 0.101
  72. Effects of extended pleurectomy and decortication on quality of life and pulmonary function in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2015 May; 99(5):1775-80.
    View in: PubMed
    Score: 0.099
  73. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.
    View in: PubMed
    Score: 0.098
  74. Radiologic-pathologic correlation of mesothelioma tumor volume. Lung Cancer. 2015 Mar; 87(3):278-82.
    View in: PubMed
    Score: 0.097
  75. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01; 20(23):5927-36.
    View in: PubMed
    Score: 0.095
  76. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 2014; 9(9):e105919.
    View in: PubMed
    Score: 0.095
  77. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer. 2014 Sep; 85(3):429-34.
    View in: PubMed
    Score: 0.094
  78. Variability of tumor area measurements for response assessment in malignant pleural mesothelioma. Med Phys. 2013 Aug; 40(8):081916.
    View in: PubMed
    Score: 0.088
  79. Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol. 2013 Apr; 8(4):478-86.
    View in: PubMed
    Score: 0.086
  80. Disease volumes as a marker for patient response in malignant pleural mesothelioma. Ann Oncol. 2013 Apr; 24(4):999-1005.
    View in: PubMed
    Score: 0.084
  81. Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012 Nov; 7(11):1728-34.
    View in: PubMed
    Score: 0.083
  82. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330.
    View in: PubMed
    Score: 0.083
  83. Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. Ann Thorac Surg. 2012 Oct; 94(4):1086-92.
    View in: PubMed
    Score: 0.082
  84. Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report. J Thorac Oncol. 2012 Apr; 7(4):755-9.
    View in: PubMed
    Score: 0.080
  85. Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. Int Surg. 2012 Jan-Mar; 97(1):65-70.
    View in: PubMed
    Score: 0.079
  86. Quantitative measurement of lung reexpansion in malignant pleural mesothelioma patients undergoing pleurectomy/decortication. Acad Radiol. 2011 Mar; 18(3):294-8.
    View in: PubMed
    Score: 0.073
  87. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010 Oct; 5(10):1655-61.
    View in: PubMed
    Score: 0.072
  88. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009 Jun 20; 27(18):3007-13.
    View in: PubMed
    Score: 0.065
  89. Protein kinase C beta in malignant pleural mesothelioma. Anticancer Drugs. 2008 Oct; 19(9):841-8.
    View in: PubMed
    Score: 0.063
  90. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15; 113(4):808-14.
    View in: PubMed
    Score: 0.062
  91. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008 Jul 20; 26(21):3567-72.
    View in: PubMed
    Score: 0.062
  92. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21.
    View in: PubMed
    Score: 0.061
  93. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71.
    View in: PubMed
    Score: 0.061
  94. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007 Sep 01; 13(17):5144-9.
    View in: PubMed
    Score: 0.058
  95. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58.
    View in: PubMed
    Score: 0.057
  96. The cancer and leukemia group B respiratory committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3581s-8s.
    View in: PubMed
    Score: 0.053
  97. Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. Ann Oncol. 2006 Nov; 17(11):1615-9.
    View in: PubMed
    Score: 0.053
  98. Variability in mesothelioma tumor response classification. AJR Am J Roentgenol. 2006 Apr; 186(4):1000-6.
    View in: PubMed
    Score: 0.053
  99. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
    View in: PubMed
    Score: 0.052
  100. Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans. Acad Radiol. 2005 Oct; 12(10):1301-9.
    View in: PubMed
    Score: 0.051
  101. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res. 2005 Mar 15; 11(6):2300-4.
    View in: PubMed
    Score: 0.049
  102. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 2004 May; 44(2):251-9.
    View in: PubMed
    Score: 0.046
  103. Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys. 2004 May; 31(5):1105-15.
    View in: PubMed
    Score: 0.046
  104. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003 Apr 15; 21(8):1556-61.
    View in: PubMed
    Score: 0.043
  105. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002 Feb; 29(1):82-96.
    View in: PubMed
    Score: 0.040
  106. High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. Lung Cancer. 2001 Nov; 34(2):289-95.
    View in: PubMed
    Score: 0.039
  107. Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging. 2004 Jul; 20(1):122-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.